Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CADILA HEALTHCARE Mar-20 |
ADCOCK INGRAM Jun-14 |
CADILA HEALTHCARE/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 352 | 360 | - | |
Low | Rs | 207 | 260 | - | |
Sales per share (Unadj.) | Rs | 139.2 | 107.2 | - | |
Earnings per share (Unadj.) | Rs | 11.8 | -27.0 | - | |
Cash flow per share (Unadj.) | Rs | 18.6 | -22.4 | - | |
Dividends per share (Unadj.) | Rs | 3.50 | 0 | - | |
Dividend yield (eoy) | % | 1.3 | 0 | - | |
Book value per share (Unadj.) | Rs | 101.4 | 84.1 | - | |
Shares outstanding (eoy) | m | 1,023.74 | 168.78 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.0 | 2.9 | 69.4% | |
Avg P/E ratio | x | 23.7 | -11.5 | -206.8% | |
P/CF ratio (eoy) | x | 15.0 | -13.9 | -108.6% | |
Price / Book Value ratio | x | 2.8 | 3.7 | 74.8% | |
Dividend payout | % | 29.8 | 0 | - | |
Avg Mkt Cap | Rs m | 286,033 | 52,343 | 546.5% | |
No. of employees | `000 | 13.4 | 4.3 | 312.3% | |
Total wages/salary | Rs m | 24,145 | 3,285 | 735.0% | |
Avg. sales/employee | Rs Th | 10,632.7 | 4,214.0 | 252.3% | |
Avg. wages/employee | Rs Th | 1,801.2 | 765.2 | 235.4% | |
Avg. net profit/employee | Rs Th | 898.5 | -1,061.8 | -84.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 142,531 | 18,091 | 787.9% | |
Other income | Rs m | 1,139 | 127 | 899.1% | |
Total revenues | Rs m | 143,670 | 18,217 | 788.6% | |
Gross profit | Rs m | 24,198 | -3,135 | -771.9% | |
Depreciation | Rs m | 6,965 | 781 | 892.0% | |
Interest | Rs m | 3,418 | 490 | 697.5% | |
Profit before tax | Rs m | 14,954 | -4,279 | -349.5% | |
Minority Interest | Rs m | 288 | -12 | -2,414.5% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 3,198 | 267 | 1,196.0% | |
Profit after tax | Rs m | 12,044 | -4,558 | -264.2% | |
Gross profit margin | % | 17.0 | -17.3 | -98.0% | |
Effective tax rate | % | 21.4 | -6.2 | -342.2% | |
Net profit margin | % | 8.5 | -25.2 | -33.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,154 | 13,250 | 657.8% | |
Current liabilities | Rs m | 82,694 | 7,455 | 1,109.2% | |
Net working cap to sales | % | 3.1 | 32.0 | 9.8% | |
Current ratio | x | 1.1 | 1.8 | 59.3% | |
Inventory Days | Days | 71 | 111 | 64.4% | |
Debtors Days | Days | 94 | 124 | 75.7% | |
Net fixed assets | Rs m | 133,236 | 7,723 | 1,725.1% | |
Share capital | Rs m | 1,024 | 84 | 1,219.1% | |
Net worth | Rs m | 103,757 | 14,199 | 730.7% | |
Long term debt | Rs m | 32,146 | 4,990 | 644.2% | |
Total assets | Rs m | 236,866 | 26,824 | 883.1% | |
Interest coverage | x | 5.4 | -7.7 | -69.5% | |
Debt to equity ratio | x | 0.3 | 0.4 | 88.2% | |
Sales to assets ratio | x | 0.6 | 0.7 | 89.2% | |
Return on assets | % | 6.5 | -15.2 | -43.0% | |
Return on equity | % | 11.6 | -32.1 | -36.2% | |
Return on capital | % | 13.7 | -19.8 | -69.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 25,054 | 1,544 | 1,622.5% | |
From Investments | Rs m | -10,123 | -474 | 2,135.0% | |
From Financial Activity | Rs m | -10,942 | 4,529 | -241.6% | |
Net Cashflow | Rs m | 3,989 | 5,599 | 71.2% |
Compare CADILA HEALTHCARE With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare CADILA HEALTHCARE With: JUBILANT LIFE SCIENCES PROCTER & GAMBLE HEALTH AUROBINDO PHARMA SANOFI INDIA NOVARTIS
Indian share markets witnessed huge buying interest during the extended closing hours today and ended their day on a strong note.
For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsIn this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More